We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

70 hedge funds and large institutions have $28.2M invested in Galectin Therapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $2.84M | Put options by funds: $1.23M

11% more capital invested

Capital invested by funds: $25.3M → $28.2M (+$2.9M)

1.33% less ownership

Funds ownership: 13.62% → 12.29% (-1.3%)

7% less funds holding

Funds holding: 75 → 70 (-5)

36% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 14

48% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 23

Holders
70
Holders Change
-5
Holders Change %
-6.67%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
12
Reduced
23
Closed
14
Calls
$2.84M
Puts
$1.23M
Net Calls
+$1.61M
Net Calls Change
+$551K

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$447K
2
KeyBank National Association
KeyBank National Association
Ohio
+$339K
3
Capstone Investment Advisors
Capstone Investment Advisors
New York
+$143K
4
QAM
QCI Asset Management
New York
+$102K
5
Citadel Advisors
Citadel Advisors
Florida
+$82.8K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$1.22M
2
Millennium Management
Millennium Management
New York
-$740K
3
TEE
Tibra Equities Europe
United Kingdom
-$316K
4
Marshall Wace
Marshall Wace
United Kingdom
-$152K
5
ECM
ExodusPoint Capital Management
New York
-$135K
Name Holding Trade Value Shares
Change 		Change in
Stake
WS
26
Wedbush Securities
California
$120K +$44.1K +13,000 +72%
Citadel Advisors
27
Citadel Advisors
Florida
$95K +$82.8K +24,432 New
HKAM
28
Horizon Kinetics Asset Management
New York
$93K – – –
BFEC
29
Benjamin F. Edwards & Company
Missouri
$92K -$37.6K -11,093 -32%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$90K -$3 -1 -0%
CF
31
Centaurus Financial
California
$88K +$23.7K +7,000 +45%
Bank of Montreal
32
Bank of Montreal
Ontario, Canada
$80K – – –
Charles Schwab
33
Charles Schwab
California
$68K – – –
Goldman Sachs
34
Goldman Sachs
New York
$57K -$11.7K -3,458 -19%
WANY
35
Wealthspire Advisors (New York)
New York
$54K – – –
Neuberger Berman Group
36
Neuberger Berman Group
New York
$53K – – –
RJA
37
Raymond James & Associates
Florida
$51K +$44.4K +13,096 New
Rockefeller Capital Management
38
Rockefeller Capital Management
New York
$49K +$8.47K +2,500 +24%
SKK
39
Shepherd Kaplan Krochuk
Massachusetts
$47K – – –
Dimensional Fund Advisors
40
Dimensional Fund Advisors
Texas
$46K -$339 -100 -0.8%
Commonwealth Equity Services
41
Commonwealth Equity Services
Massachusetts
$46K +$40.3K +11,902 New
William Blair & Company
42
William Blair & Company
Illinois
$42K – – –
BSW
43
Buckingham Strategic Wealth
Missouri
$42K +$36.4K +10,734 New
VCM
44
Vivaldi Capital Management
Illinois
$41K – – –
Renaissance Technologies
45
Renaissance Technologies
New York
$39K -$1.22M -360,103 -97%
DAS
46
Dynamic Advisor Solutions
Arizona
$39K – – –
Wells Fargo
47
Wells Fargo
California
$33K -$12K -3,543 -29%
MAM
48
Meeder Asset Management
Ohio
$30K +$9.71K +2,866 +58%
Bank of America
49
Bank of America
North Carolina
$21K -$22.7K -6,700 -55%
GI
50
Gradient Investments
Minnesota
$15K – – –
1
2
3 4

GALT Hedge Fund Activity: Q3 2021 in Review

70 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2021, worth a combined $28.2M — up 11% from $25.3M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of GALT and 9 opened new positions — a net loss of 5 holders — while 23 trimmed existing stakes and 12 added.

The largest buyer was Geode Capital Management, adding an estimated $447K. The largest seller was Renaissance Technologies, cutting an estimated $1.22M.

  • 70 institutional investors held Galectin Therapeutics (GALT) as of Q3 2021, down from 75 in Q2 2021.
  • Funds reported $28.2M of Galectin Therapeutics stock for Q3 2021, up 11% quarter-over-quarter.
  • 9 funds opened new Galectin Therapeutics positions in Q3 2021 and 14 closed out, a net change of -5 holders.
  • The largest Galectin Therapeutics buyer in Q3 2021 was Geode Capital Management, an estimated $447K added.
  • The largest Galectin Therapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $1.22M sold.

Based on aggregated 13F filings for Q3 2021.